PathogenFinder2 is a new AI tool developed by researchers at DTU in Denmark, in collaboration with international partners, to ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, presented early-stage cost-effectiveness analysis of its ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today a $73M Series B financing round led by ...

Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in ...

Discover the collaboration between Ochsner Health and Cognito Therapeutics to advance brain health innovations in New Orleans ...

Cognito Therapeutics, which is in late-stage development of its device to treat neurodegenerative diseases like Alzheimer’s, hauled in $105 million in an oversubscribed series C funding round. The ...

CAMBRIDGE, Mass., March 17, 2026--(BUSINESS WIRE)--Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive therapies for neurodegenerative diseases, today announced ...